Cigna vs Centene
CI and CNC side by side, both in accident and health insurance and medical. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CI and CNC compare
Cigna is the larger company, worth 2.3 times as much as Centene ($79.7B against $34.9B).
On earnings, Cigna is cheaper: it trades at 13.3× trailing earnings, against 24.1× for Centene.
Centene grew revenue faster over the last twelve months (9.7% versus 6.8% for Cigna).
Cigna keeps more of each dollar of sales as profit, with a net margin of 2.1% compared with 0.72% at Centene.
Cigna pays a dividend yielding 2.1%; Centene does not pay one.
Cigna scores higher on the StockData Score (16 against 8 for Centene), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CI | CNC |
|---|---|---|
| Size and price | ||
| Market cap | $79.7B | $34.9B |
| Share price | $301.45 | $70.48 |
| Change, 1 year | 16.8% | 106% |
| Change, 5 years | 43.2% | −3.5% |
| Beta (5Y) | 0.34 | 0.50 |
| Employees | 68K | 61K |
| StockData Score | ||
| Total score | 16 (better) | 8 |
| Valuation score | 6 (better) | 2 |
| Growth score | 2 | 2 |
| Performance score | 3 (better) | 2 |
| Health score | 2 | 2 |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 13.3× (better) | 24.1× |
| P/S | 0.3× | 0.2× (better) |
| P/B | 1.8× | 1.6× (better) |
| EV/EBITDA | 8.2× (better) | 12.0× |
| P/FCF | – | 8.8× |
| PEG | 11.23 | – |
| FCF yield | – | 11.3% |
| Fair value | $383.88 | $69.68 |
| Margin of safety | 21.5% (better) | −1.1% |
| Growth | ||
| Revenue growth (TTM) | 6.8% | 9.7% (better) |
| Revenue growth, 5Y average | 11.4% | 11.9% (better) |
| EPS growth (TTM) | −0.04% | – |
| EPS growth, 5Y average | −0.69% | – |
| Profitability | ||
| Gross margin | 20.7% (better) | 7.9% |
| Operating margin | 3.4% (better) | 0.49% |
| Net margin | 2.1% (better) | 0.72% |
| FCF margin | – | 1.9% |
| Return on equity | 14.1% (better) | 6.8% |
| Return on invested capital | 11.4% (better) | 4.6% |
| Financial health | ||
| Debt / equity | 0.72 | 0.70 (better) |
| Net debt / EBITDA | 1.88 (better) | −3.60 |
| Interest coverage | 7.1× (better) | 1.6× |
| Current ratio | 0.84 | 1.16 (better) |
| Altman Z-score | 2.83 | 3.28 (better) |
| Piotroski F-score | 7 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 2.1% | – |
| Payout ratio | 27.2% | – |
| Years of dividend growth | 5 | – |
| Dividend growth, 5Y average | 173% | – |
| Buyback yield | 1.7% (better) | 0.07% |
| Shareholder yield | 3.7% (better) | 0.07% |
| Ownership | ||
| Held by institutions | 89.9% | 98.6% |
| Held by insiders | 0.41% | 0.79% |
| Insider net buying, 12 months | −$66.8M | −$14.6M (better) |
| Superinvestors holding | 4 (better) | 3 |
| Short interest, % of float | 2.4% | 2.1% |
Go deeper
- CI stock overview
- CI income statement
- CI valuation and score
- CNC stock overview
- CNC income statement
- CNC valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.